Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 19, 2005. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons regarding the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
On October 18, 2005, Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("the GSK Trust"), transferred 8,607 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The company was advised of these transactions on October 19, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(b). The GSK Trust is identified as a discretionary trust where all current and former employees are potential beneficiaries. Three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the shares held by the trust in the same capacity as other employees.
Investor Verification Points
- Verify the total number of shares transferred (8,607) and the specific plan involved (SmithKline Beecham Employee Share Option Plan 1991).
- Confirm the date of the transaction (October 18, 2005) versus the date of company notification (October 19, 2005).
- Note that this filing does not contain financial performance data for the period.